References

1. Hsu YC, Wang LF, Lee KW, Ho KY, Huang CJ, Kuo WR. Cerebral radionecrosis in patients with nasopharyngeal carcinoma. Kaohsiung J Med Sci. 2005; 21(10):452-459. PubMed | Google Scholar


2. Fischer AW, Holfelder H. Lokales Amyloid in Gehirn: Eine spatfolge von rontgenbestrahlungen. Dtsch Z Chir. 1930; 227: 475-483. Google Scholar


3. Lee AWM, Kwong DLW, Leung S-F, Tung SYT, Sze W-M, Sham JST. Factors affecting risk of symptomatic temporal necrosis: significance of fractional dose and treatment time. Int J Radiation Oncology Biol Phys. 2002; 53 (1):75-85. PubMed | Google Scholar


4. Nasr Ben Ammar C, Chaari N, Kochbati L, Attia I, Ben Hamadi D, Chebbi A, Saadi A, Besbes M, Maalej M. Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases. Cancer Radiother. 2007; 11(5):234-240. PubMed | Google Scholar


5. Patsouris A, Augereau P, Tanguy JY, Morel O, Menei P, Rousseau A, Paumier A. Differential diagnosis of local tumor recurrence or radionecrosis after stereotactic radiosurgery for treatment of brain metastasis. Cancer Radiother. 2014; 18(2):142-146. PubMed | Google Scholar


6. Dufour MA, Papin-Michaud C, Vandenbos F, Bourg V, Bondiau PY,Chanalet S, Fauchon F, Fontaine D, Saada E, Darcourt J. Impact de la TEP à la 18F-DOPA sur la décision thérapeutique en RCP lors du diagnostic différentiel entre radionécrose et récidive de néoplasie cérébrale. Médecine Nucléaire. 2014; 38(3): 132-134. PubMed | Google Scholar


7. Gronier S, Bourg V, Frenay M, Cohen M, Mondot L, Thomas P, Lebrun C. Bevacizumab for the treatment of cerebral radionecrosis.Rev Neurol. 2011; 167(4):331-336. PubMed | Google Scholar


8. Lee AW, Foo W, Chappell R, et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 40(1):35-42. PubMed | Google Scholar